...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The British journal of psychiatry : >Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia
【24h】

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

机译：未发表的评分量表：精神分裂症治疗的随机对照试验中偏倚的主要来源

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background A recent review suggested an association between using unpublished scales in clinical trials and finding significant results. Aims To determine whether such an association existed in schizophrenia trials. Method Three hundred trials were randomly selected from the Cochrane Schizophrenia Group's Register. All comparisons between treatment groups and control groups using rating scales were identified. The publication status of each scale was determined and claims of a significant treatment effect were recorded. Results Trials were more likely to report that a treatment was superior to control when an unpublished scale was used to make the comparison (relative risk 1.37 (95% C11.12-1.68)). This effect increased when a a€? gold-standarda€? definition of treatment superiority was applied (RR 1.94(95%C11.35-2.79)). In non-pharmacological trials, one-third of a€? gold-standarda€? claims of treatment superiority would not have been made if published scales had been used. Conclusions Unpublished scales are a source of bias in schizophrenia trials.
机译：背景技术最近的一项评论表明，在临床试验中使用未发表的量表与发现重要结果之间存在关联。目的确定精神分裂症试验中是否存在这种关联。方法从Cochrane精神分裂症组的登记册中随机选择300个试验。确定了治疗组和对照组之间使用等级量表进行的所有比较。确定每种量表的出版状态，并记录明显的治疗效果。结果当使用未发表的量表进行比较时，试验更有可能报告治疗优于对照（相对风险1.37（95％C11.12-1.68））。当一个？黄金标准？定义了治疗优势（RR 1.94（95％C11.35-2.79））。在非药物试验中，只有三分之一黄金标准？如果使用已发布的量表，就不会有治疗优势的声明。结论未发表的量表是精神分裂症试验中偏见的来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号